Does Rallies show Form 4 insider transactions for HRMY?

Yes. Rallies tracks HRMY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is HRMY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HRMY. It does not provide personalized investment advice.

HRMY (Harmony Biosciences Holdings, Inc. Common Stock) Stock Analysis - Insider Trades

Harmony Biosciences Holdings, Inc. Common Stock (HRMY) is a publicly traded Healthcare sector company. As of May 21, 2026, HRMY trades at $32.74 with a market cap of $1.73B and a P/E ratio of 12.41. HRMY moved +3.09% today. Year to date, HRMY is -14.61%; over the trailing twelve months it is -11.90%. Its 52-week range spans $25.52 to $41.61. Analyst consensus is buy with an average price target of $43.44. Rallies surfaces HRMY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading HRMY stock inside the company?

Recent HRMY insider activity includes Kapadia Sandip sold 3.75K, Kapadia Sandip sold 20.96K, Dayno Jeffrey M. sold 20.00K, Dayno Jeffrey M. sold 5.93K, and Kapadia Sandip sold 20.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

HRMY Key Metrics

Key financial metrics for HRMY
Metric	Value
Price	$32.74
Market Cap	$1.73B
P/E Ratio	12.41
EPS	$2.53
Dividend Yield	0.00%
52-Week High	$41.61
52-Week Low	$25.52
Volume	19
Avg Volume	0
Revenue (TTM)	$899.11M
Net Income	$145.62M
Gross Margin	76.55%

Recent HRMY Insider Trades

Kapadia Sandip sold 3.75K (~$139.17K) on Jan 26, 2026.
Kapadia Sandip sold 20.96K (~$752.83K) on Jan 15, 2026.
Dayno Jeffrey M. sold 20.00K (~$802.15K) on Dec 12, 2025.
Dayno Jeffrey M. sold 5.93K (~$237.96K) on Dec 12, 2025.
Kapadia Sandip sold 20.00K (~$790.90K) on Dec 5, 2025.

Latest HRMY News

Harmony Biosciences Raises 2026 Revenue Estimate to $1.02B, Cuts EPS to $3.58 — May 6, 2026
Harmony Biosciences Posts $243.8M Q4 Growth, Guides $1B+ WAKIX 2026 Sales — Feb 24, 2026
Analysts See Over 30% Revenue Growth for Harmony Biosciences in Q4 2025 Preview — Feb 23, 2026
Harmony Biosciences EPS Estimate Jumps 7.5% to $4.00 — Feb 20, 2026
Analysts Lift Harmony Biosciences’ 2026 EPS to $4.00 While Shares Drop 7.8% — Feb 20, 2026

HRMY Analyst Consensus

9 analysts cover HRMY: 0 strong buy, 5 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $43.44.

Common questions about HRMY

Who is trading HRMY stock inside the company?: Recent HRMY insider activity includes Kapadia Sandip sold 3.75K, Kapadia Sandip sold 20.96K, Dayno Jeffrey M. sold 20.00K, Dayno Jeffrey M. sold 5.93K, and Kapadia Sandip sold 20.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HRMY?: Yes. Rallies tracks HRMY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HRMY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HRMY. It does not provide personalized investment advice.